Earnings ·
Unicycive Therapeutics reported a net loss of $1.7 million, or $0.06 per share, for the second quarter ended June 30…
UNCYUnicycive Therapeutics, Inc.
Unicycive Therapeutics reported a net loss of $1.7 million, or $0.06 per share, for the second quarter ended June 30, 2026, compared to a $6.5 million loss in the prior year period, driven by a $8.4 million gain from the change in fair value of its warrant liability. The company holds $61.4 million in cash and marketable securities as of June 30, 2026, providing expected runway into 2027. Operationally, Unicycive received a Complete Response Letter for its New Drug Application for oxylanthanum carbonate due to manufacturing deficiencies at a third-party vendor; however, the FDA has now assigned an inspection to this facility, which is a prerequisite for resubmitting the application. The company continues commercial readiness initiatives while awaiting inspection results. Unicycive Therapeutics operates in the biotechnology industry, developing therapies for kidney diseases.